SARS-CoV-2 vaccination and myositis in Norway and Sweden
Open Access
- 22 November 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Abstract
Objective: The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines. Methods: We conducted a population-based cohort study in Norway and Sweden of 13 million persons who turned 12 years or older in 2021 and were residents at the start of follow-up on 27 December 2020. The participants were followed until incident diagnosis of myositis, censoring, or the end of the study (21 May 2023). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% CIs, comparing rates in risk periods (day 0 up to and including day 180 after each dose) with rates in unvaccinated periods. Corrections for potential confounding were made by adjusting for sex, age, occupation (health-care worker), region, positive COVID-19 test, and comorbidities. Results: We observed 101 myositis events in 7 002 398 unvaccinated person-years and 99 myositis events within 180 days of any combination of mRNA vaccines (6 241 529 person-years), and 13 with the adenoviral vector vaccine (445 256 person-years). The adjusted IRRs for the 180-day risk periods following any combination of mRNA vaccines and the adenoviral vector vaccine were 0.84 (95% CI, 0.63–1.11) and 1.31 (0.72–2.36), respectively, compared with unvaccinated periods. The estimates for each specific first, second and third dose of mRNA were similar to the estimate of all doses combined. Conclusion: In this nationwide study of >13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.Keywords
This publication has 10 references indexed in Scilit:
- Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United StatesVaccine, 2024
- Idiopathic inflammatory myopathies linked to vaccination against SARS-CoV-2: a systematic reviewReumatismo, 2023
- COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case reportImmunologic Research, 2023
- Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 vaccine: A case report and brief reviewRevue Neurologique, 2023
- A case series of dermatomyositis following SARS-CoV-2 vaccinationFrontiers in Medicine, 2022
- Incidence of Dermatomyositis in a Nationwide Cohort Study of US VeteransJAMA Dermatology, 2022
- Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic reviewFrontiers in Public Health, 2022
- SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million ResidentsJAMA Cardiology, 2022
- Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemicPharmacoepidemiology and Drug Safety, 2019
- Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based studyRheumatology, 2017